Atazavanir/Ritonavir-based HAART in Children

Phase 2 Completed 20 enrolled The HIV Netherlands Australia Thailand Research Collaboration National Health Security Office, Thailand · collab The Thai Government Pharmaceutical Organization (GPO) · collab amfAR, The Foundation for AIDS Research · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

There are no data on efficacy, safety and pharmacokinetics of ATV/r-based HAART in HIV-infected Asian children. Therefore, the investigators aim to evaluate the pharmacokinetics, efficacy and safety of ATV/r-based HAART in Thai HIV-infected children.

Timeline

Start: 2011-07
Primary completion: 2013-02
Completion: 2013-02

Publications

Results Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T; HIV-NAT 146 Study Team. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate. Pediatr Infect Dis J. 2014 Dec;33(12):e316-9. doi: 10.1097/INF.0000000000000469.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	200 mg	Oral
Background	Ritonavir	Other / unclassified	100 mg	Oral

Atazavanir/Ritonavir-based HAART in Children

Summary

Timeline

Publications

Drugs

Indications